Early treatment after first MS-like attack reduces long-term risk
People who experience a first attack of multiple sclerosis (MS)-like disease are less likely to experience long-term disability progression…
Articles by Marisa Wexler, MS
Diet shows no association with relapses, disability progression
A higher quality diet is associated with reductions in certain types of brain lesions in multiple sclerosis (MS), but…
Immune cells in skull’s bone marrow appear to have unique profile
Immune cells in the skull’s bone marrow show distinct molecular profiles from those of other bones throughout the body, and…
Biomarker found for potential new disorder that’s been labeled as MS
An antibody biomarker may help to distinguish people with a disease that resembles multiple sclerosis (MS), but may actually…
New PET imaging approach captures inflammation before lesions evident
A new imaging technique was able to detect inflammation in a mouse model of multiple sclerosis (MS) before disease…
Cognitive health likely to affect person’s sense of sexual satisfaction
Estimates of the prevalence of sexual dysfunction with multiple sclerosis (MS), as well of its risk factors, differ depending…
Relapses found to drive disability worsening in 1st years of MS
In people with relapsing forms of multiple sclerosis (MS), relapses that occur in the first few years after the…
Gut bacteria may be key to activate immune cells that trigger MS
Pro-inflammatory immune cells that can target the brain may be activated in a specific region of the intestine by certain…
Octave raises $30M to speed commercialization of care program
Octave Bioscience has raised $30 million in financing to help accelerate commercialization efforts for its precision care program for…
AI model is able to predict MS risk years before disease onset
A new artificial intelligence (AI) algorithm could help identify people at risk of developing multiple sclerosis (MS). “Our model’s…
PB006, biosimilar of Tysabri, favored for approval in European Union
The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended that PB006,…
Boosting energy production in nerve fibers may help treat MS
In multiple sclerosis (MS), inflammation leads to less energy production in nerve fibers by reducing the levels of enzymes…
Phase 1 trial of bryostatin-1 in MS expected by year’s end
Synaptogenix is teaming up with Cleveland Clinic for a Phase 1 clinical trial involving people with multiple sclerosis…
Can elderly MS patients safely stop treatment? Study aims to find out.
A first-of-its-kind study is aiming to determine whether older adults with multiple sclerosis (MS) can safely stop taking…
With Korro Bio merger in works, Frequency stops program for MS
With a planned merger in the works, Frequency Therapeutics is no longer advancing its remyelination therapies for multiple…
Use of oral DMTs grew substantially since their launch: US study
Since their launch in the 2010s, the use of oral disease-modifying treatments (DMTs) for multiple sclerosis (MS) has increased…
Positive results found for new under-the-skin Ocrevus formulation
A new formulation of Ocrevus (ocrelizumab), given as a 10-minute under-the-skin injection, was comparable to the approved intravenous version…
Inflammation in brain membranes may act as trigger in MS: Study
Inflammation in the membranes around the brain may trigger an inflammatory response that can spread into nearby brain tissue, a…
Imcyse joins EU project to develop tools to better track MS progression
The biopharmaceutical company Imcyse has signed on to a new project that aims to use artificial intelligence (AI) to…
Pregnancy hormone estriol promotes myelin repair in MS mice
Treatment with estriol, a hormone that’s produced during pregnancy, reduced disease severity and promoted myelin repair in the cortex —…
PoNS device wins accreditation needed to be covered by Medicare
The PoNS device — officially the Portable Neuromodulation Stimulator, designed to help improve walking ability in people with…
Ocrevus appears to be better than rituximab at preventing MS relapses
Ocrevus (ocrelizumab) appears to be more effective than rituximab at reducing relapse activity in people with relapsing-remitting…
30 years after MS was first treatable, challenges remain amid triumphs
It’s been three decades since the first treatment for multiple sclerosis (MS) was approved. In that time, the field…
DDX39B seen as ‘guardian’ in autoimmune attacks that drive MS
The protein DDX39B is a master regulator of immune tolerance, or the immune system’s ability to distinguish self from potentially…
Aerobic, resistance exercises most effective for patient fitness: Study
For people with multiple sclerosis (MS), all forms of exercise are likely to be beneficial for physical fitness, but…
Molecular mechanisms help drive microglia problems in brain in MS
Disease-associated inflammatory activity of microglia — a type of immune cell with a central role in the development of…
Researchers analyze switching to Kesimpta from oral therapies
People with relapsing multiple sclerosis (MS) who experienced disease activity while on oral therapies had less disease activity after…
Novel immune cell strategy found to reverse disease in MS mice
Microparticles that activate regulatory T-cells, or Tregs, an immune cell type with anti-inflammatory properties, reversed the accumulation of physical disability…
Analyses of protein levels in blood can help ID MS patient subgroups
Analyses of protein levels in the blood can be used to identify groups of multiple sclerosis (MS) patients with…
Vidofludimus calcium tolerated well for nearly 4 years
Long-term treatment with vidofludimus calcium (IMU-838) has been tolerated well overall among people with relapsing-remitting MS (RRMS), new…